Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.92% | 32.36% | 11.34% | 21.63% | -18.20% |
| Total Depreciation and Amortization | -36.36% | -29.95% | -30.57% | -30.86% | -1.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -76.96% | -60.61% | 18.13% | -36.52% | 215.95% |
| Change in Net Operating Assets | 155.26% | -83.89% | 101.93% | -975.08% | 54.43% |
| Cash from Operations | 16.13% | 17.15% | 23.89% | -1.38% | 24.12% |
| Capital Expenditure | -1,116.33% | -345.05% | -2,570.59% | -1,290.70% | 45.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.75% | -9.57% | 139.07% | 152.12% | -49.68% |
| Cash from Investing | 21.10% | -16.45% | 136.71% | 146.47% | -49.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -46.01% | -- | -31.70% | -- | -- |
| Cash from Financing | -46.01% | -- | 4.00% | -- | 1,838.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 424.12% | 84.16% | 95.65% | -88.84% | -121.71% |